(A071101) A Phase II Randomized Trial Comparing the Efficacy of Heat Shock Protein-Peptide Complex -96 (HSPPC-96) (NSC #725085, Alliance IND #15380) Vaccine Given with Bevacizumab Versus Bevacizumab Alone in the Treatment of Surgically Resectable Recurrent Glioblastoma Multiforme (GBM)
Description: 
To determine whether there is an overall survival advantage of HSPPC-96 administered with bevacizumab, given concomitantly or at the point of progression, in comparison with bevacizumab alone in patients with surgically resectable recurrent GBM.
Study Number: 

NCG 280615

Phase: 
2
Principal Investigator: 
ClinicalTrials.Gov ID: 
NCT01814813

To inquire about participating in these studies, call 1-877-ASK-RPCI (1-877-275-7724) or e-mail askrpci@roswellpark.org.